Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Anrikefon Injection for Multimodal Postoperative Analgesia in Patients Undergoing Laparoscopic Hepatectomy
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Summary
A single-center, randomized, double-blind, placebo-controlled trial design will be adopted to investigate whether Anruikefon can significantly reduce the consumption of sufentanil via PCIA pumps within 48 hours postoperatively compared with placebo.
Official title: Efficacy and Safety of Anrikefon Injection for Multimodal Postoperative Analgesia in Patients Undergoing Laparoscopic Hepatectomy:A Single-center, Randomized, Double-blind, Placebo-controlled Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
117
Start Date
2026-08-30
Completion Date
2027-07-30
Last Updated
2026-09-03
Healthy Volunteers
No
Conditions
Interventions
Anruikefon 1 μg/kg per dose Group
Anruikefon 1 μg/kg/dose, once every 8 hours (q8h), for a total of 6 doses.
Anruikefon 100 μg per dose Group
Anruikefon 100 μg per dose, once every 8 hours (q8h), for a total of 6 doses.
Control group
0.9% Sodium Chloride Injection, via intravenous bolus injection, once every 8 hours (q8h), for a total of 6 doses.
Locations (1)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China